Peer Tfelt-Hansen

Dr. Peer Tfelt-Hansen


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2012 in Cephalalgia
Verified
Journal Article
Closed access
PDF file
PTPeer Tfelt-Hansen
Peer Tfelt-Hansen
JPJulio Pascual
Julio Pascual
NRNabih Ramadan
Nabih Ramadan
CDCarl Dahlöf
Carl Dahlöf
DDDomenico D’Amico
Domenico D’Amico
TSTodd Schwedt
Todd Schwedt


25 April 2008 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
LLL. H. Lassen
L. H. Lassen
VJV. B. Jacobsen
V. B. Jacobsen
PHP. A. Haderslev
P. A. Haderslev
BSB. Sperling
B. Sperling
HIHelle Klingenberg Iversen
Helle Klingenberg Iversen
PTPeer Tfelt-Hansen
Peer Tfelt-Hansen
Calcitonin gene-related peptide (CGRP)-containing nerves are closely associated with cranial blood vessels. CGRP is the most potent vasodilator known in isolated cerebral blood vessels. CGRP can induce migraine attacks, and two selective CGRP receptor antagonists are effective in the treatment of migraine attacks. It is therefore important to investigate its mechanism of action in patients with migraine. We here investigate the effects of intravenous human alpha-CGRP (hαCGRP) on intracranial hemodynamics. In a double-blind, cross-over study, the effect of intravenous infusion of hαCGRP (2 μg/min) or placebo for 20 min was studied in 12 patients with migraine without aura outside attacks. Xenon-133 inhalation SPECT-determined regional cerebral blood flow (rCBF) and transcranial Doppler (TCD)-determined blood velocity (Vmean) in the middle cerebral artery (MCA), as well as the heart rate and blood pressure, were the outcome parameters. No change of rCBF was observed at the end of infusion [1.2% ± 1.7 with hαCGRP, vs. −1.6% ± 3.1 with placebo (mean ± SD)] (P = 0.43). Vmean in MCA decreased to 13.5% ± 3.6 with hαCGRP versus 0.6% ± 1.8 with placebo (P < 0.005). Since rCBF was unchanged, this indicates a dilation of the MCA. hαCGRP induced a decrease in MAP (12%) (P < 0.005) and an increase in heart rate (58%) (P < 0.0001). CGRP dilates cerebral arteries, but the effect is so small that it is unlikely to be the only mechanism of CGRP-induced migraine.

10 December 2009 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
PTPeer Tfelt-Hansen
Peer Tfelt-Hansen
The Journal of Headache and Pain is a peer-reviewed open access journal published under the brand SpringerOpen. It is specifically dedicated to researchers involved in all aspects of headache and related pain, including theory, methodology, clinical practice and care. The journal's scope is broad, reflecting the wide application of scientific advances to every branch of headache and related pain management. Within a multidisciplinary perspective, the Journal covers headache and related pain syndromes in the following fields: genetics, neurology, internal medicine, clinical pharmacology, child neuropediatrics, anesthesiology, rheumatology, otology, dentistry, neurotraumatology, neurosurgery, psychiatry, pain management, and addiction. The Journal of Headache and Pain publishes original papers, reviews, rapid communications, brief reports, and letters pertinent to the various aspects of headache and related pain. Researchers in all basic and clinical fields of headache and related pain, from molecular biology to genetics, from epidemiology to classification, from quality of life assessment to clinical trials, are becoming increasingly aware of the importance of this medical specialty. Official Journal of the European Headache Federation Official Journal of Lifting The Burden - The Global Campaign against Headache For authors and readers: All articles are published under the Creative Commons Attribution licence. You can read, redistribute and reuse the articles for free, as long as you cite the authors of the original work properly. The journal went open access in 2011, which means that all articles published since then are freely available online.

1 May 2012 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
PTPeer Tfelt-Hansen
Peer Tfelt-Hansen
NONiels Jørgen Olesen
Niels Jørgen Olesen

28 March 2009 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
PTPeer Tfelt-Hansen
Peer Tfelt-Hansen
HLHan Le
Han Le
The involvement of calcitonin gene-related peptide (CGRP) in migraine pathophysiological mechanisms is shown by the facts that CGRP can induce migraine and that two CGRP antagonists, olcegepant and telcagepant, are effective in the treatment of migraine attacks. Increase of the neuropeptide CGRP during migraine and cluster headache attacks in the extracerebral circulation as measured in the external jugular vein (EJV) has been regarded as an established fact. Then in 2005, a study, using the migraine patients as their own controls, showed; however, no changes of CGRP in EJV. For migraine there is thus some uncertainty as to whether CGRP is increased in all migraine patients and more research is needed. In contrast, there are three ‘positive’ studies in cluster headache in which both sumatriptan, O2 and spontaneous resolution normalized CGRP. The source of an increase of CGRP in EJV is most likely a ‘nervous vasodilatory drive’ in the extracranial vascular bed. It remains an enigma how the observed increase of CGRP in the EJV fits into the mechanisms of migraine and cluster headache.